OpenAI is officially throwing its weight behind a package of legislation in the US Congress designed to shut down a specific, terrifying loophole: the use of artificial intelligence to engineer biological weapons. A company spokesperson confirmed on Tuesday that the ChatGPT maker is endorsing the Web of Biological Data Act, the AI-Ready Bio-Data Standards Act, and the Scale Biology Act. This isn't just a press release; it's a direct intervention in the legislative process to stop AI models from accelerating the threat of synthetic viruses. The endorsement was first reported by Politico, but OpenAI’s direct confirmation signals a shift from vague ethical guidelines to concrete legal support.
The stakes here are biological, not just digital. The bills aim to secure the data pipelines that AI models use to understand and potentially design pathogens. OpenAI is also backing a critical piece of the broader FRONTIER Act, which mandates that leading AI companies must embed independent evaluators to assess the safety of their models before they are deployed. This requirement forces a third-party check on the very systems that could, if misused, help create a pandemic.
This offensive legislative stance follows a week of heightened anxiety in the tech sector. Last week, OpenAI explicitly stated it was pushing for mandatory national AI safety requirements in the United States. Heads of top US AI labs, including those at OpenAI, have publicly called for a slowdown in the pace of advanced AI development. The company is no longer waiting for regulation; it is helping to write the rules. The underlying fear is that the gap between the complexity of AI and the biological knowledge it can access is widening, creating a risk that no single company can manage alone.
Congress must now decide whether to act on these endorsements. The bills are bipartisan, which gives them a better chance of passage than purely partisan tech regulations. The next step is a formal review by the relevant committees, where the specific language of the 'Web of Biological Data Act' will be scrutinized. If passed, these laws would set a global precedent for how AI companies are held accountable for the dual-use nature of their technology. The window for voluntary self-regulation is closing, and OpenAI is betting that Congress will step in before the technology outpaces the law.